For Q1 FY2026 ended March 31, 2026, Kailera Therapeutics reported no revenue and a net loss of $78.9 million, a 338.6% increase from the prior year. Operating loss was $84.7 million, up 313.8% year-over-year. Diluted EPS was -$3,650, reflecting a 79.7% improvement. Cash stood at $111.8 million, while shareholders' equity was negative $432.1 million.
•No revenue generated in Q1 FY2026.
•Net loss widened to $78.9 million from $18.0 million in Q1 FY2025.
•Operating loss increased to $84.7 million from $20.5 million.
•Cash and cash equivalents totaled $111.8 million as of March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist.
Its portfolio also includes KAI-7535, an oral small molecule GLP-1 receptor agonist, and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. Founded in 2024, the company is based in Waltham, Massachusetts.
Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and related metabolic conditions. The company's pipeline includes injectable peptides, oral peptides, and oral small molecules. Its lead program is KAI-9531, an injectable GLP-1/GIP receptor dual agonist. Additionally, Kailera is developing KAI-7535, an oral small molecule GLP-1 receptor agonist, and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. The company holds exclusive global development and commercialization rights for four metabolic disease assets outside of Greater China, with therapies delivered through both oral and injectable formulations.
Where is Kailera Therapeutics (KLRA) listed and in which currency?
Kailera Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol KLRA. The company's stock trades in US dollars (USD). As a US-based company listed on a major US exchange, its financial reporting and share pricing are denominated in USD, making it accessible to investors trading on US markets.
What sector and industry does Kailera Therapeutics (KLRA) belong to?
Kailera Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing novel therapies for obesity and related conditions. Biotechnology companies like Kailera typically engage in drug discovery, preclinical studies, and clinical trials to bring new treatments to market, often with a high degree of scientific innovation and regulatory oversight.
Where is Kailera Therapeutics (KLRA) headquartered and what is its geographic focus?
Kailera Therapeutics is headquartered in Waltham, Massachusetts, United States. The company was founded in 2024 and operates primarily in the US. While its headquarters are in Massachusetts, its development and commercialization rights extend globally outside of Greater China, indicating a broad geographic strategy for its metabolic disease assets. The company's therapies are being developed for worldwide markets, with a focus on addressing obesity and related conditions.
What are the key product candidates in Kailera Therapeutics' (KLRA) pipeline?
Kailera Therapeutics' pipeline includes several promising candidates for obesity and metabolic diseases. The lead program is KAI-9531, an injectable GLP-1/GIP receptor dual agonist designed to target two key hormone receptors involved in appetite and glucose regulation. Another notable candidate is KAI-7535, an oral small molecule GLP-1 receptor agonist, which offers a convenient oral administration route. Additionally, KAI-4729 is an injectable GLP-1/GIP/glucagon receptor tri-agonist, targeting three receptors for enhanced efficacy. The company also holds exclusive rights to four metabolic disease assets from Greater China, covering both oral and injectable formulations.